The latest price of evantumumab in 2024 announced by the entire network

Introduction: Evantumumab is a single agent indicated for the treatment of adult patients with locally advanced or metastatic NSCLC who have an EGFR exon 20 insertion mutation detected by an FDA-approved test and whose disease has progressed during or after platinum-based chemotherapy.

The latest price of evantuzumab in 2024

is relatively expensive, and the specific price will vary depending on factors such as region, hospital, and drug specifications. It is understood that the price of a box of evantumumab produced by Janssen Pharmaceuticals in the United States is approximately between $10,300 and $11,000. The price may change and may not reflect the current market price or the actual selling price in a specific region.

Drug prices are affected by many factors, including production costs, market demand, medical insurance policies, etc., so prices will continue to change. If you need to check the latest price of evantumumab in 2024, it is recommended that you directly contact the drug production company, pharmacy, insurance company, or obtain the latest price information through official drug pricing inquiry channels. In addition, hospital pharmacies or professional medical consulting agencies may also provide relevant price information.

Effectiveness of evantumumab in the treatment of lung cancer

In a phase 3 international randomized trial, patients with advanced NSCLC with EGFR exon 20 insertion were assigned to the intravenous evantumumab combined with chemotherapy group or the chemotherapy alone group, in which the patients had not received systemic therapy. A total of 308 patients were randomized, with 153 receiving evantumumab plus chemotherapy and 155 receiving chemotherapy alone.

The study showed that the progression-free survival of the evantuzumab combined with chemotherapy group was significantly longer than that of the chemotherapy group, with a median of 11.4 months and 6.7 months respectively. The hazard ratio of disease progression or death was 0.40. At 18 months, 31% of patients in the evantuzumab combined with chemotherapy group reported progression-free survival, compared with 3% of the chemotherapy group. At data cutoff, 73% and 47% of patients reported complete or partial responses. As a first-line treatment for patients with advanced NSCLC with EGFR exon 20 insertion, evantumumab combined with chemotherapy is more effective than chemotherapy alone.